|
|
Long-term
survival of glioblastoma multiforme: importance of histopathological
reevaluation
Kraus JA, Wenghoefer M,
Schmidt MC, von Deimling A, Berweiler U, Roggendorf W, Diete S, Dietzmann K,
Muller B, Heuser K, Reifenberger G, Schlegel U
Department
of Neurology, University of Bonn Medical Center, Germany.
The overall prognosis for patients with glioblastoma multiforme is extremely
poor.
However, a small proportion of patients enjoy prolonged survival.
This study investigated retrospectively the extent to which erroneous
histopathological classification may contribute to long-term survival of
patients initially diagnosed with "glioblastoma multiforme."
We compared two age- and gender-matched patient groups with different
postoperative time to tumor progression (TTP), defined as "short-term"
for TTP of less than 6 months (n = 54), and "long-term" for TTP of
more than 12 months (n = 52).
Histological specimens of the corresponding tumors, all primarily diagnosed as
glioblastoma multiforme, were reevaluated according to the current World Health
Organization (WHO) classification of central nervous system tumors, with the
investigators being blinded to clinical outcome.
Among the tumors from short-term TTP patients, one tumor (2%) was reclassified
as anaplastic oligoastrocytoma (WHO grade III) while the remaining 53 were
confirmed as glioblastoma multiforme.
In contrast, 13 tumors (25%) from the long-term TTP patients were reclassified,
mostly as anaplastic oligodendroglioma (WHO grade III; n = 7) or anaplastic
oligoastrocytoma (WHO grade III, n = 2), respectively.
In addition, three were reclassified as anaplastic astrocytoma (WHO grade III),
and one was identified as anaplastic pilocytic astrocytoma (WHO grade
III).
Our data indicate that a sizable proportion of glioblastoma patients with
long-term survival actually carry malignant gliomas with oligodendroglial
features.
The correct histopathological recognition of these tumors has not only
prognostic but also therapeutic implications, since oligodendroglial tumors are
more likely to respond favorably to chemotherapy.
PMID: 10929275 [PubMed - indexed for MEDLINE]
Source: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10929275&dopt=Abstract
|